ASH: Argenx cues up a second use for efgartigimod
pharmaphorum
DECEMBER 12, 2022
Adverse events such as bruising, headaches, and blood in urine occurred at roughly the same frequency in both groups of patients in ADVANCE IV, and while serious side effects were seen in 8% of the Vyvgart group, that was lower than the 16% reported with placebo.
Let's personalize your content